• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗高血压治疗掩盖了家族因素对血压变异的影响。

Antihypertensive treatments obscure familial contributions to blood pressure variation.

作者信息

Cui Jisheng S, Hopper John L, Harrap Stephen B

机构信息

Centre for Genetic Epidemiology, The University of Melbourne, Parkville, Victoria, Australia.

出版信息

Hypertension. 2003 Feb;41(2):207-10. doi: 10.1161/01.hyp.0000044938.94050.e3.

DOI:10.1161/01.hyp.0000044938.94050.e3
PMID:12574083
Abstract

The linkage and association between inherent blood pressure and underlying genotype is potentially confounded by antihypertensive treatment. We estimated blood pressure variance components (genetic, shared environmental, individual-specific) in 767 adult volunteer families by using a variety of approaches to adjusting blood pressure of the 244 subjects (8.2%) receiving antihypertensive medications. The additive genetic component of variance for systolic pressure was 73.9 mm Hg(2) (SE, 8.8) when measured pressures (adjusted for age by gender within each generation) were used but fell to 61.4 mm Hg(2) (SE, 8.0) when treated subjects were excluded. When the relevant 95th percentile values were substituted for treated systolic pressures, the additive genetic component was 81.9 mm Hg(2) (SE, 9.5), but individual adjustments in systolic pressure ranged from -53.5 mm Hg to +64.5 mm Hg (mean, +17.2 mm Hg). Instead, when 10 mm Hg was added to treated systolic pressure, the additive genetic component rose to 86.6 mm Hg(2) (SE, 10.1). Similar changes were seen in the shared environment component of variance for systolic pressure and for the combined genetic and shared environmental (ie, familial) components of diastolic pressure. There was little change in the individual-specific variance component across any of the methods. Therefore, treated subjects contribute important information to the familial components of blood pressure variance. This information is lost if treated subjects are excluded and obscured by treatment effects if unadjusted measured pressures are used. Adding back an appropriate increment of pressure restores familial components, more closely reflects the pretreatment values, and should increase the power of genomic linkage and linkage disequilibrium analyses.

摘要

内在血压与潜在基因型之间的联系和关联可能会因抗高血压治疗而混淆。我们通过多种方法对767个成年志愿者家庭中接受抗高血压药物治疗的244名受试者(8.2%)的血压进行调整,估计了血压方差成分(遗传、共享环境、个体特异性)。当使用测量血压(按每代性别调整年龄)时,收缩压方差的加性遗传成分是73.9 mmHg²(标准误,8.8),但排除治疗对象后降至61.4 mmHg²(标准误,8.0)。当用相关的第95百分位数代替治疗后的收缩压时,加性遗传成分是81.9 mmHg²(标准误,9.5),但收缩压的个体调整范围为-53.5 mmHg至+64.5 mmHg(均值,+17.2 mmHg)。相反,当给治疗后的收缩压加上10 mmHg时,加性遗传成分升至86.6 mmHg²(标准误,10.1)。收缩压方差的共享环境成分以及舒张压的综合遗传和共享环境(即家族性)成分也有类似变化。个体特异性方差成分在任何方法中变化都很小。因此,治疗对象为血压方差的家族性成分贡献了重要信息。如果排除治疗对象,这些信息就会丢失;如果使用未经调整的测量血压,则会被治疗效果掩盖。加上适当的压力增量可恢复家族性成分,更准确地反映治疗前的值,并应增加基因组连锁和连锁不平衡分析的效能。

相似文献

1
Antihypertensive treatments obscure familial contributions to blood pressure variation.抗高血压治疗掩盖了家族因素对血压变异的影响。
Hypertension. 2003 Feb;41(2):207-10. doi: 10.1161/01.hyp.0000044938.94050.e3.
2
Familial and genomic analyses of postural changes in systolic and diastolic blood pressure.收缩压和舒张压姿势变化的家族性及基因组分析。
Hypertension. 2004 Mar;43(3):586-91. doi: 10.1161/01.HYP.0000118044.84189.44. Epub 2004 Feb 9.
3
Genes and family environment explain correlations between blood pressure and body mass index.
Hypertension. 2002 Jul;40(1):7-12. doi: 10.1161/01.hyp.0000022693.11752.e9.
4
Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.在一项随机对照试验中,六类抗高血压药物对脉压的影响。
Hypertension. 2001 Oct;38(4):953-7. doi: 10.1161/hy1001.096212.
5
Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.中国高血压患者中α1A-肾上腺素能受体Arg347Cys多态性及血浆厄贝沙坦浓度与血压治疗反应的个体及联合关联
Clin Pharmacol Ther. 2005 Sep;78(3):239-48. doi: 10.1016/j.clpt.2005.06.003.
6
Heritability of daytime ambulatory blood pressure in an extended twin design.扩展双生子设计中白昼动态血压的遗传度
Hypertension. 2005 Jan;45(1):80-5. doi: 10.1161/01.HYP.0000149952.84391.54. Epub 2004 Nov 22.
7
Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.收缩压和舒张压的差异控制:社区中血压控制不佳的相关因素。
Hypertension. 2000 Oct;36(4):594-9. doi: 10.1161/01.hyp.36.4.594.
8
Association of antihypertensive therapy and diastolic hypotension in chronic kidney disease.慢性肾脏病中降压治疗与舒张期低血压的关联
Hypertension. 2007 Sep;50(3):474-80. doi: 10.1161/HYPERTENSIONAHA.107.088088. Epub 2007 Jul 30.
9
Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).伴有或不伴有心血管疾病患者舒张压降低的效果:SPRINT(收缩压干预试验)分析。
Hypertension. 2018 May;71(5):840-847. doi: 10.1161/HYPERTENSIONAHA.117.10177. Epub 2018 Mar 26.
10
Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood Institute Family Heart Study.血压与高血压的全基因组扫描:美国国立心肺血液研究所家族心脏研究
Hypertension. 2002 Jul;40(1):1-6. doi: 10.1161/01.hyp.0000022660.28915.b1.

引用本文的文献

1
Genome-wide pleiotropy analysis of longitudinal blood pressure and harmonized cognitive performance measures.纵向血压与协调认知功能指标的全基因组多效性分析
Alzheimers Dement. 2025 Sep;21(9):e70681. doi: 10.1002/alz.70681.
2
The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank.脂蛋白(a)与心血管疾病风险中常见心血管危险因素的相互作用:基于英国生物银行的证据
Am J Prev Cardiol. 2025 May 22;22:101008. doi: 10.1016/j.ajpc.2025.101008. eCollection 2025 Jun.
3
Diagnostic and prognostic value of ECG-predicted hypertension-mediated left ventricular hypertrophy using machine learning.
利用机器学习评估心电图预测的高血压介导的左心室肥厚的诊断和预后价值
J Hypertens. 2025 Aug 1;43(8):1327-1338. doi: 10.1097/HJH.0000000000004034. Epub 2025 May 23.
4
Long-Term Changes to Cardiovascular Biomarkers After Hormone Therapy in the Women's Health Initiative Hormone Therapy Clinical Trials.女性健康倡议激素治疗临床试验中激素治疗后心血管生物标志物的长期变化
Obstet Gynecol. 2025 Apr 1;145(4):357-367. doi: 10.1097/AOG.0000000000005862. Epub 2025 Feb 27.
5
Epigenomics and transcriptomics association study of blood pressure and incident diagnosis of hypertension in twins.双胞胎血压与高血压发病诊断的表观基因组学和转录组学关联研究
Hypertens Res. 2025 Apr;48(4):1599-1612. doi: 10.1038/s41440-025-02164-5. Epub 2025 Feb 19.
6
Associations of life-course cardiovascular risk factors with late-life cerebral hemodynamics.终生心血管危险因素与晚年脑血流动力学的关联。
J Cereb Blood Flow Metab. 2025 Apr;45(4):765-778. doi: 10.1177/0271678X241301261. Epub 2024 Nov 17.
7
Marginal interaction test for detecting interactions between genetic marker sets and environment in genome-wide studies.全基因组研究中用于检测遗传标记集与环境之间相互作用的边际相互作用检验。
G3 (Bethesda). 2025 Jan 8;15(1). doi: 10.1093/g3journal/jkae263.
8
Serum vitamin D, blood pressure and hypertension risk in the HUNT study using observational and Mendelian randomization approaches.观察性研究和孟德尔随机化方法探讨 HUNT 研究中血清维生素 D、血压与高血压风险的关系。
Sci Rep. 2024 Jun 21;14(1):14312. doi: 10.1038/s41598-024-64649-6.
9
A novel index for measuring the impact of devices on hypertension.一种用于衡量设备对高血压影响的新指标。
Sci Rep. 2023 Aug 22;13(1):13651. doi: 10.1038/s41598-023-39943-4.
10
A genome-wide by PM exposure interaction study for blood pressure in Korean adults.全基因组范围内的 PM 暴露与韩国成年人血压的交互作用研究。
Sci Rep. 2023 Aug 11;13(1):13060. doi: 10.1038/s41598-023-40155-z.